Page last updated: 2024-09-04

pomalidomide and 2019 Novel Coronavirus Disease

pomalidomide has been researched along with 2019 Novel Coronavirus Disease in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Anderson, L; Basker, N; Basu, S; Bygrave, C; Chauhan, SR; Djebbari, F; Eyre, TA; Firas, AK; Gudger, A; Karim, F; Lam, HPJ; Maddams, R; Morgan, L; Ngu, L; Obeidalla, A; Panitsas, F; Poynton, M; Prideaux, S; Ramasamy, K; Rampotas, A; Salhan, B; Sangha, G; Soutar, R; Triantafillou, M; Tsagkaraki, I; Vallance, G; Walker, M; Yang, L; Young, J	1

Other Studies

1 other study(ies) available for pomalidomide and 2019 Novel Coronavirus Disease

Article	Year
Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study. Hematology (Amsterdam, Netherlands), 2022, Volume: 27, Issue:1 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Pandemics; Retrospective Studies; Thalidomide; United Kingdom	2022

Article

Year

Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study.

Hematology (Amsterdam, Netherlands), 2022, Volume: 27, Issue:1

Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Pandemics; Retrospective Studies; Thalidomide; United Kingdom

2022